择期EVAR术后对比剂急性肾损伤预测模型:安全对比剂用量阈值
基于VQI数据库49,417例择期EVAR患者,2.6%发生PC-AKI;PC-AKI与30天死亡率独立相关(OR 8.79),每增加10 mL对比剂PC-AKI风险增加5%;建立的预测模型(AUC 0.732)利用13个患者变量推荐个体化安全对比剂用量。
要点
- 择期EVAR后PC-AKI发生率为2.6%,与30天死亡率独立相关(OR 8.79)。
- 对比剂每增加10 mL,PC-AKI风险增加5%(OR per mL 1.005)。
- 预测模型基于13个术前变量推荐个体化安全对比剂用量,AUC 0.732。
核心结论
- PC-AKI对择期EVAR术后患者发病率和死亡率有显著影响,预测模型可推荐个体化对比剂用量以降低PC-AKI风险。
研究设计与样本
- 基于血管质量倡议(VQI)数据库的回顾性队列研究,纳入49,417例择期EVAR患者,排除透析、肾移植、术中肾动脉覆盖或支架、开放转开腹者,采用分样本法建立并验证预测模型。
主要发现
- 49,417例择期EVAR患者中2.6%(n=1300)发生PC-AKI。
- PC-AKI组30天死亡率为12%,无PC-AKI组为0.5%(P < .001)。
- PC-AKI组2年生存率为74.5%,无PC-AKI组为82.8%(P < .001)。
- PC-AKI与围术期死亡率独立相关(OR 8.79;95%CI 6.60-11.64)。
- 对比剂用量与PC-AKI独立相关(每mL OR 1.005;95%CI 1.004-1.006),即每10 mL对比剂PC-AKI风险增加5%。
关键数值与推荐
- 预测模型使用13个简单的患者特异性变量生成推荐对比剂用量以最小化PC-AKI风险。
- 模型区分度AUC 0.732(95%CI 0.706-0.759)。
临床怎么用
- 在缺乏择期EVAR对比剂最佳用量指南的情况下,该模型可术前指导术者选择个体化对比剂用量以降低PC-AKI风险。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Post-contrast acute kidney injury (PC-AKI) is a serious complication of endovascular abdominal aortic aneurysm repair (EVAR) associated with development of chronic kidney disease, prolonged hospital stay, and perioperative mortality. Iodinated contrast is a known risk factor for PC-AKI but is a technical necessity for EVAR. The optimal volume of contrast necessary to minimize risk of PC-AKI in a patient undergoing elective EVAR is unknown. This study examines the incidence and significance of PC-AKI after EVAR and derives a patient-specific model to determine the optimal volume of contrast the surgeon should administer to mitigate the risk of PC-AKI. METHODS: The Vascular Quality Initiative database was queried for patients who underwent elective EVAR. Patients with history of dialysis, kidney transplant, intraoperative coverage of a renal artery or renal artery stenting, or open conversion were excluded. Patients were stratified by development of PC-AKI. Patient characteristics were compared using bivariate and then multivariable logistic regression analysis to select key significant variables. A prediction model was developed for PC-AKI using a split-sample approach with a model training dataset and a validation dataset. The 30-day postoperative mortality for this same patient cohort was evaluated using bivariate and multivariable logistic regression analysis. Kaplan-Meier curve analysis compared survival between groups. RESULTS: Among 49,417 patients undergoing elective EVAR, 2.6% (n = 1300) developed PC-AKI. Patients with PC-AKI were older with higher incidence of preoperative comorbidities and developed significantly more postoperative complications, including 30-day mortality (12% vs 0.5%; P < .001), compared with patients without PC-AKI. Patients who developed PC-AKI also had lower survival on Kaplan-Meier analysis (2-year survival: 74.5% vs 82.8%; P < .001). Regression analysis accounted for all other factors and showed that PC-AKI was independently associated with perioperative mortality (odds ratio [OR], 8.79; 95% confidence interval [CI], 6.60-11.64). On multivariable logistic regression, PC-AKI was independently associated with volume of contrast given (OR per mL, 1.005; 95% CI, 1.004-1.006) translating to a 5% increased PC-AKI risk for every 10 mL of contrast administered. The prediction model (area under the curve = 0.732; 95% CI, 0.706-0.759) provides surgeons with a recommended patient-specific safe volume of contrast that minimizes the risk of PC-AKI based on preoperative patient characteristics. CONCLUSIONS: PC-AKI has significant impact on patient morbidity and mortality after elective EVAR. The model provided utilizes 13 simple, patient-specific variables to generate a recommended contrast volume to minimize PC-AKI risk. In the absence of established guidelines for optimal volume of contrast to administer during elective EVAR, this model can serve as an important guide for surgeons prior to performing EVAR.
引用
- Bader JM, Li Y, Lee C, et al. Prediction model for safe contrast volume thresholds to prevent postcontrast acute kidney injury after endovascular abdominal aortic aneurysm repair. J Vasc Surg. 2025. PMID: 40490161. doi:10.1016/j.jvs.2025.05.041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。